Bao L Nguyen

US Patent:

6716851, Apr 6, 2004

Filed:

Dec 12, 2001

Appl. No.:

10/012444

Inventors:

Sui Xiong Cai - San Diego CA
John A. Drewe - Carlsbad CA
Bao Nguyen - San Diego CA
Azra Pervin - San Marcos CA

Assignee:

Cytovia, Inc. - San Diego CA

International Classification:

A61K 31505

US Classification:

514275, 514211, 514213, 5142305, 514272, 514273, 544 51, 544 52, 544114, 544238, 544330, 544331

Abstract:

The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: wherein A, Ar , Ar , R and R are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

US Patent:

6794400, Sep 21, 2004

Filed:

Jun 3, 2002

Appl. No.:

10/158827

Inventors:

Sui Xiong Cai - San Diego CA
Bao Ngoc Nguyen - San Diego CA
John Drewe - Carlsbad CA
P. Sanjeeva Reddy - San Diego CA
Shailaja Kasibhatla - San Diego CA
Azra Pervin - San Diego CA

Assignee:

Cytovia, Inc. - San Diego CA

International Classification:

A61K 3144

US Classification:

514357, 514406, 514471

Abstract:

The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: wherein A , A , Q and R -R are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

US Patent:

7226927, Jun 5, 2007

Filed:

Nov 10, 2003

Appl. No.:

10/704448

Inventors:

Sui Xiong Cai - San Diego CA, US
John A Drewe - Carlsbad CA, US
P. Sanjeeva Reddy - San Diego CA, US
Bao Nguyen - San Diego CA, US
Azra Pervin - San Marcos CA, US

Assignee:

Cytovia, Inc. - San Diego CA

International Classification:

A61K 31/53
A61K 31/505
A61K 31/506
C07D 239/02
C07D 409/00
C07D 251/00
C07C 49/00
C07C 255/17

US Classification:

514256, 514241, 544180, 544326, 544328

Abstract:

The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I:.

US Patent:

7256219, Aug 14, 2007

Filed:

Mar 14, 2002

Appl. No.:

10/471720

Inventors:

Sui Xiong Cai - San Diego CA, US
P. Sanjeeva Reddy - San Diego CA, US
John A. Drewe - Carlsbad CA, US
Bao Ngoc Nguyen - San Diego CA, US
Shailaja Kasibhatla - San Diego CA, US

Assignee:

Cytovia, Inc. - San Diego CA

International Classification:

A61K 31/12
C07C 49/00
C07D 333/00
C07D 307/02
C07D 221/02
C07D 209/04
C07D 207/18

US Classification:

514681, 514685, 568327, 568334, 549 49, 549379, 549505, 546112, 548469, 548565

Abstract:

The present invention is directed to multifluoro-substituted Chalcones and analogs thereof, represented by the general Formula I:.

US Patent:

7314887, Jan 1, 2008

Filed:

Oct 21, 2005

Appl. No.:

11/256572

Inventors:

E. Adam Kallel - Escondido CA, US
Thomas Lau - San Diego CA, US
Matthew H. McNeill - San Clemente CA, US
Todd A. Miller - San Marcos CA, US
Bao N. Nguyen - San Diego CA, US
Richard J. Penuliar - San Diego CA, US
Dean P. Phillips - San Marcos CA, US
Daniel A. Ruppar - San Antonio TX, US
Lin Zhi - San Diego CA, US
Jackline E. Dalgard - Del Mar CA, US

Assignee:

Ligand Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/404
C07D 209/40

US Classification:

514418, 548483

Abstract:

Disclosed herein are compounds of Formula (I), (II), and (III).

US Patent:

7475323, Jan 6, 2009

Filed:

Feb 9, 2005

Appl. No.:

11/054773

Inventors:

Ling Hang - San Diego CA, US
Bao Nguyen - San Diego CA, US

Assignee:

Qualcomm Incorporated - San Diego CA

International Classification:

H03M 13/00

US Classification:

714758

Abstract:

A higher layer at a base station generates and passes messages to Layer 2, which generates and appends a CRC value to each message. The messages are encapsulated in frames at the physical layer, which generates and appends a CRC value to each frame. The base station transmits the frames on a control channel. The physical layer at a wireless device processes the control channel and decodes each received frame to obtain a decoded frame. The physical layer forwards the decoded frame to Layer 2, regardless of whether the frame passes or fails a CRC test. Layer 2 processes the decoded frame, even if the decoded frame fails the CRC test, to extract messages sent in the decoded frame. Layer 2 checks each extracted message based on its CRC value and forwards each message that passes the CRC test to the higher layer.

US Patent:

7691895, Apr 6, 2010

Filed:

Nov 8, 2007

Appl. No.:

11/937392

Inventors:

E. Adam Kallel - Escondido CA, US
Thomas Lau - San Diego CA, US
Matthew H. McNeill - San Clemente CA, US
Todd A. Miller - San Marcos CA, US
Bao N. Nguyen - San Diego CA, US
Dean P. Phillips - San Marcos CA, US
Daniel A. Ruppar - San Antonio TX, US
Lin Zhi - San Diego CA, US
Jackline E. Dalgard - Del Mar CA, US

Assignee:

Ligand Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/404
C07D 209/40

US Classification:

514418, 548483

Abstract:

Disclosed herein are compounds of Formula (I), (II), and (III).

US Patent:

7696365, Apr 13, 2010

Filed:

Jul 28, 2004

Appl. No.:

10/900958

Inventors:

Jie Fei Cheng - Carlsbad CA, US
Bao Ngoc Nguyen - San Diego CA, US
Xuewei Liu - Los Angeles CA, US
Gary D. Lopaschuk - Edmonton, CA
Jason R. Dyck - Sherwood Park, CA

Assignee:

Chugai Seiyaku Kabushiki Kaisha - Tokyo

International Classification:

C07D 307/00

US Classification:

549468

Abstract:

The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.